Nanobiotix Announces Promising Preclinical Data for Nanoprimer Technology

New data shows Nanoprimer can improve systemic bioavailability and reduce toxicity for LNP-delivered DNA immunotherapies

Apr. 20, 2026 at 6:59am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in muted blues, greens, and grays, depicting interlocking geometric shapes and flowing organic forms that suggest the complex interplay of biological and technological systems at a microscopic scale.Nanobiotix's Nanoprimer platform aims to enhance the delivery and reduce the toxicity of advanced lipid nanoparticle-based therapies, unlocking new possibilities in cancer treatment and beyond.Cambridge Today

Nanobiotix, a late-stage biotech company, presented new preclinical data at the 2026 AACR Annual Meeting evaluating its Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA (LNP-DNA) therapies. The data showed that pre-treatment with Nanoprimer increased systemic bioavailability, reduced hepatic toxicity, and lowered cGAS-STING related inflammation compared to LNP-DNA alone.

Why it matters

Rapid liver clearance is a key limitation of LNP-DNA therapies, reducing their systemic bioavailability and tumor accumulation while also increasing hepatic toxicity. The Nanoprimer platform is designed to transiently occupy hepatic clearance pathways to improve delivery and reduce off-target effects, potentially unlocking new therapeutic possibilities for advanced treatments.

The details

In the preclinical mouse study, LNP-DNA vehicles designed for anti-tumor immunotherapy were administered with or without Nanobiotix Nanoprimer pre-treatment. The data showed that Nanoprimer pre-treatment led to increased systemic bioavailability, reduced hepatic toxicity, and lower cGAS-STING related inflammation compared to LNP-DNA alone.

  • The data was presented at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) on April 20, 2026.

The players

Nanobiotix

A late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases.

Laurent Levy

Nanobiotix Chief Executive Officer and Chairman of the Executive Board.

Earli

A collaborator with Nanobiotix on the preclinical research.

Got photos? Submit your photos here. ›

What they’re saying

“We continue our dual path approach to the development of our next-wave Nanoprimer platform in which we are both pursuing external collaborations with partners developing innovative therapeutic candidates that are challenged by liver accumulation, as well as our own proprietary internal pipeline.”

— Laurent Levy, Nanobiotix Chief Executive Officer and Chairman of the Executive Board

What’s next

Nanobiotix plans to further evaluate the Nanoprimer platform in sequence with innovative LNP-delivered therapies to improve systemic bioavailability and reduce toxicity.

The takeaway

The Nanoprimer platform shows promise in overcoming a key limitation of LNP-DNA therapies by improving systemic delivery and reducing off-target effects in the liver. This could unlock new therapeutic possibilities for advanced treatments in oncology and beyond.